Neuropeptide Injection

Neuropeptide injection is a clinically-used, prescription-only therapy composed of low-molecular-weight neuropeptides and amino acids. It mimics the action of naturally occurring nerve growth factors and is specifically designed to support the repair and protection of the central nervous system.

With over 40 years of use in multiple countries, neuropeptide injections are widely applied as supportive treatment in the following situations:

✅ Functional recovery after stroke or traumatic brain injury

✅ Enhancement of memory, attention, and cognitive response

✅ Slowing cognitive decline (e.g. Alzheimer’s disease, mild cognitive impairment)

✅ Relief of brain fog, mental fatigue, and neuro-metabolic instability

Cerebrolysin®

• Improves Motor and Cognitive Functions in Stroke and TBI

• Improves Cognitive performance in demantiac

• Helps prevent Cognitive decline after stroke and TBI

Cerebrolysin® is a neurotrophic agent whose main components are peptides derived from protein hydrolysis. It targets the pathological mechanisms of both acute and chronic central nervous system disorders, helping to protect the brain, promote repair, and support neuronal regeneration¹^–³.

It exerts its neurorestorative effects via two major pathways: NTF^# and Shh^##, producing a dual mechanism of neural repair².

Clinical imaging and trials demonstrate that Cerebrolysin® promotes neuronal repair, whereas placebo does not³.

Therapeutic areas¹

---

Stroke, Cognitive Impairment, and Brain Injury¹

During stroke, cerebral blood flow is blocked, leading to ischemia, neuronal death, and irreversible brain damage⁵. Treatment with Cerebrolysin® after stroke has been shown to promote neuronal repair⁴.

Clinical studies confirm that combining Cerebrolysin® with standard rehabilitation accelerates stroke recovery, improves motor outcomes, and enhances quality of life⁶ ⁷.

In particular, Cerebrolysin® significantly improves upper limb motor function and reduces disability in stroke patients when used alongside standard rehabilitation⁷.

Alzheimer’s Disease ^{8 9}

Alzheimer’s disease is a progressive neurodegenerative disorder and one of the most common geriatric conditions. Abnormalities in neurons lead to continuous cognitive decline, ultimately resulting in dementia¹⁰.

Cerebrolysin® has demonstrated neuroprotective properties, with clinical studies showing improvement in cognitive function and overall clinical condition in patients with Alzheimer’s disease⁸ ⁹.

It is particularly beneficial for patients with more severe Alzheimer’s disease, showing meaningful improvements in cognition⁸.

Vascular Cognitive Impairment¹¹

Vascular cognitive impairment (VCI) is the second most common cause of cognitive decline after Alzheimer’s disease, resulting from cerebrovascular pathology¹².

Common symptoms include impaired attention, poor information processing, reduced decision-making ability, depression, and apathy¹².

A clinical study in patients with mild-to-moderate VCI demonstrated that Cerebrolysin® led to sustained cognitive improvements¹¹.

---

References

1. Cerebrolysin® Hong Kong Prescribing Information. July 2002.

2. Fiani B, Reardon MA, Ayres A, et al. Current applications of Cerebrolysin®. Neurosci. 2021;42:1345-53.

3. Chang WH, Park CH, Kim DY, et al. Cerebrolysin combined with rehabilitation for functional recovery after stroke. BMC Neurol. 2016;16:31.

4. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis and angiogenesis after ischemic stroke in rats. J Neurosci Res. 2010;88:3275-81.

5. Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020;21:7609.

6. Lang W, Stadler CH, Poljakovic Z, et al. A randomized, placebo-controlled trial of Cerebrolysin in acute ischemic stroke. Int J Stroke. 2013;8(2):95-104.

7. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and recovery after stroke (CARS). Stroke. 2016;47:151-9.

8. Ruether E, et al. Cerebrolysin in dementia: results and perspectives. In: Ageing and Dementia – Current and Future Concepts. Springer-Verlag/Wien; 2002. p. 265-75.

9. Alvarez XA, Cacabelos R, Laredo M, et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2011;8:583-91.

10. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397:1577-90.

11. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: a randomized, double-blind, placebo-controlled clinical trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-8.

12. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698-706.

13. Strilciuc S, Muresanu DF, et al. Neuroprotective effects of Cerebrolysin: from bench to bedside. Pharmaceuticals (Basel). 2021;14:1297.

14. European Medicines Agency. List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs). Last updated: 3 Jul 2024.

This information has been provided by EVER Pharma and is intended for reference purposes only.

---

Disclaimer

The above information is provided for general reference and informational purposes only. It does not constitute medical advice, diagnosis, or treatment—whether general or specific to any individual—nor should it replace professional medical consultation. Specific diagnoses and treatment plans must be determined by a physician based on the patient’s individual circumstances. Before considering any medical procedure, please review the relevant information carefully and consult your attending physician to ensure the most appropriate course of care.